Abstract PR13:Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade ovarian cancer

Elaine Sanij; Kate Hannan; Jiachen Xuan; Shunfei Yan; Jessica Ahern; Anna S Trigos; Natalie Brajanovski; Jinbae Son; Keefe Chan; Olga Kondrashova; Elizabeth Lieschke; Matthew Wakefield; Sarah Ellis; Gretchen Poortinga; C Cullinane; Kum Kum Khanna; Linda Mileshkin; Grant McArthur; John Soong; Els M Berns; Ross Hannan; Clare L. Scott; Karen E.  Sheppard; Richard B Pearson

doi:10.1158/1557-3265.OVCA19-PR13

Abstract PR13:Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade ovarian cancer

Elaine Sanij, Kate Hannan, Jiachen Xuan, Shunfei Yan, Jessica Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew Wakefield, Sarah Ellis, Gretchen Poortinga, C Cullinane, Kum Kum Khanna, Linda Mileshkin, Grant McArthur, John Soong, Els M BernsRoss Hannan, Clare L. Scott, Karen E. Sheppard, Richard B Pearson

Research output: Contribution to journal › Article › peer-review

Abstract

PARP inhibitors (PARPi) have revolutionized disease management of patients with homologous recombination (HR) DNA repair-deficient high-grade serous ovarian cancer (HGSOC). However, acquired resistance to PARPi is a major challenge in the clinic. The specific inhibitor of RNA polymerase I (Pol I) transcription of ribosomal RNA genes (rDNA) has demonstrated single-agent antitumor activity in p53 wild-type and p53-mutant hematologic malignancies (first-in-human trial, dose escalation study of CX-5461 at Peter MacCallum Cancer Centre) (Khot et al., Cancer Discov 2019). CX-5461 has also been reported to exhibit synthetic lethality with BRCA1/2 deficiency through stabilization of G-quadruplex DNA (GQ) structures. Here, we investigate the efficacy of CX-5461 in treating HGSOC.

Original language	English
Journal	Clinical Cancer Research
Volume	26
Issue number	13_Supplement
DOIs	https://doi.org/10.1158/1557-3265.OVCA19-PR13
Publication status	Published - 2020

Access to Document

10.1158/1557-3265.OVCA19-PR13

Cite this

Sanij, E., Hannan, K., Xuan, J., Yan, S., Ahern, J., Trigos, A. S., Brajanovski, N., Son, J., Chan, K., Kondrashova, O., Lieschke, E., Wakefield, M., Ellis, S., Poortinga, G., Cullinane, C., Khanna, K. K., Mileshkin, L., McArthur, G., Soong, J., ... Pearson, R. B. (2020). Abstract PR13:Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade ovarian cancer. Clinical Cancer Research, 26(13_Supplement). https://doi.org/10.1158/1557-3265.OVCA19-PR13

@article{5b3671b4d15e48088e4fac0da5950cda,

title = "Abstract PR13:Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade ovarian cancer",

abstract = "PARP inhibitors (PARPi) have revolutionized disease management of patients with homologous recombination (HR) DNA repair-deficient high-grade serous ovarian cancer (HGSOC). However, acquired resistance to PARPi is a major challenge in the clinic. The specific inhibitor of RNA polymerase I (Pol I) transcription of ribosomal RNA genes (rDNA) has demonstrated single-agent antitumor activity in p53 wild-type and p53-mutant hematologic malignancies (first-in-human trial, dose escalation study of CX-5461 at Peter MacCallum Cancer Centre) (Khot et al., Cancer Discov 2019). CX-5461 has also been reported to exhibit synthetic lethality with BRCA1/2 deficiency through stabilization of G-quadruplex DNA (GQ) structures. Here, we investigate the efficacy of CX-5461 in treating HGSOC.",

author = "Elaine Sanij and Kate Hannan and Jiachen Xuan and Shunfei Yan and Jessica Ahern and Trigos, \{Anna S\} and Natalie Brajanovski and Jinbae Son and Keefe Chan and Olga Kondrashova and Elizabeth Lieschke and Matthew Wakefield and Sarah Ellis and Gretchen Poortinga and C Cullinane and Khanna, \{Kum Kum\} and Linda Mileshkin and Grant McArthur and John Soong and Berns, \{Els M\} and Ross Hannan and Scott, \{Clare L.\} and Sheppard, \{Karen E.\} and Pearson, \{Richard B\}",

year = "2020",

doi = "10.1158/1557-3265.OVCA19-PR13",

language = "English",

volume = "26",

journal = "Clinical Cancer Research",

publisher = "American Association for Cancer Research",

number = "13\_Supplement",

}

Sanij, E, Hannan, K, Xuan, J, Yan, S, Ahern, J, Trigos, AS, Brajanovski, N, Son, J, Chan, K, Kondrashova, O, Lieschke, E, Wakefield, M, Ellis, S, Poortinga, G, Cullinane, C, Khanna, KK, Mileshkin, L, McArthur, G, Soong, J, Berns, EM, Hannan, R, Scott, CL, Sheppard, KE & Pearson, RB 2020, 'Abstract PR13:Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade ovarian cancer', Clinical Cancer Research, vol. 26, no. 13_Supplement. https://doi.org/10.1158/1557-3265.OVCA19-PR13

TY - JOUR

T1 - Abstract PR13:Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade ovarian cancer

AU - Sanij, Elaine

AU - Hannan, Kate

AU - Xuan, Jiachen

AU - Yan, Shunfei

AU - Ahern, Jessica

AU - Trigos, Anna S

AU - Brajanovski, Natalie

AU - Son, Jinbae

AU - Chan, Keefe

AU - Kondrashova, Olga

AU - Lieschke, Elizabeth

AU - Wakefield, Matthew

AU - Ellis, Sarah

AU - Poortinga, Gretchen

AU - Cullinane, C

AU - Khanna, Kum Kum

AU - Mileshkin, Linda

AU - McArthur, Grant

AU - Soong, John

AU - Berns, Els M

AU - Hannan, Ross

AU - Scott, Clare L.

AU - Sheppard, Karen E.

AU - Pearson, Richard B

PY - 2020

Y1 - 2020

N2 - PARP inhibitors (PARPi) have revolutionized disease management of patients with homologous recombination (HR) DNA repair-deficient high-grade serous ovarian cancer (HGSOC). However, acquired resistance to PARPi is a major challenge in the clinic. The specific inhibitor of RNA polymerase I (Pol I) transcription of ribosomal RNA genes (rDNA) has demonstrated single-agent antitumor activity in p53 wild-type and p53-mutant hematologic malignancies (first-in-human trial, dose escalation study of CX-5461 at Peter MacCallum Cancer Centre) (Khot et al., Cancer Discov 2019). CX-5461 has also been reported to exhibit synthetic lethality with BRCA1/2 deficiency through stabilization of G-quadruplex DNA (GQ) structures. Here, we investigate the efficacy of CX-5461 in treating HGSOC.

AB - PARP inhibitors (PARPi) have revolutionized disease management of patients with homologous recombination (HR) DNA repair-deficient high-grade serous ovarian cancer (HGSOC). However, acquired resistance to PARPi is a major challenge in the clinic. The specific inhibitor of RNA polymerase I (Pol I) transcription of ribosomal RNA genes (rDNA) has demonstrated single-agent antitumor activity in p53 wild-type and p53-mutant hematologic malignancies (first-in-human trial, dose escalation study of CX-5461 at Peter MacCallum Cancer Centre) (Khot et al., Cancer Discov 2019). CX-5461 has also been reported to exhibit synthetic lethality with BRCA1/2 deficiency through stabilization of G-quadruplex DNA (GQ) structures. Here, we investigate the efficacy of CX-5461 in treating HGSOC.

U2 - 10.1158/1557-3265.OVCA19-PR13

DO - 10.1158/1557-3265.OVCA19-PR13

M3 - Article

VL - 26

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 13_Supplement

ER -

Abstract PR13:Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade ovarian cancer

Abstract

Access to Document

Fingerprint

Cite this